MENA: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2024

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in MENA

The MENA's prophylactic medicaments containing insulin market was estimated at $X in 2022, stabilizing at the previous year. The total consumption indicated a buoyant expansion from 2012 to 2022: its value increased at an average annual rate of +6.3% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, consumption decreased by -1.1% against 2020 indices. Over the period under review, the market attained the maximum level at $X in 2020; however, from 2021 to 2022, consumption stood at a somewhat lower figure.

Production of Medicaments Containing Insulin But Not Antibiotics In Measured Doses in MENA

In value terms, prophylactic medicaments containing insulin production amounted to $X in 2022 estimated in export price. The total production indicated resilient growth from 2012 to 2022: its value increased at an average annual rate of +6.3% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, production decreased by -0.7% against 2020 indices. The most prominent rate of growth was recorded in 2014 with an increase of 25%. The level of production peaked at $X in 2020; however, from 2021 to 2022, production stood at a somewhat lower figure.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports in MENA

In 2022, approx. X tons of medicaments containing insulin but not antibiotics in measured doses were exported in MENA; growing by 245% against the previous year. Over the period under review, exports recorded a significant increase. As a result, the exports attained the peak and are likely to continue growth in the immediate term.

In value terms, prophylactic medicaments containing insulin exports soared to $X in 2022. In general, exports posted a significant expansion. The most prominent rate of growth was recorded in 2018 with an increase of 82%. The level of export peaked in 2022 and is expected to retain growth in the near future.

Exports by Country

In 2022, Turkey (X tons) and the United Arab Emirates (X tons) represented the largest exporter of medicaments containing insulin but not antibiotics in measured doses in MENA, mixing up 97% of total export.

From 2012 to 2022, the biggest increases were recorded for Turkey (with a CAGR of +73.7%).

In value terms, Turkey ($X) remains the largest prophylactic medicaments containing insulin supplier in MENA, comprising 66% of total exports. The second position in the ranking was taken by the United Arab Emirates ($X), with a 26% share of total exports.

In Turkey, prophylactic medicaments containing insulin exports expanded at an average annual rate of +52.4% over the period from 2012-2022.

Export Prices by Country

In 2022, the export price in MENA amounted to $X per ton, reducing by -49.9% against the previous year. Over the period under review, the export price showed a abrupt decrease. The most prominent rate of growth was recorded in 2020 an increase of 46%. As a result, the export price attained the peak level of $X per ton. From 2021 to 2022, the export prices remained at a lower figure.

Prices varied noticeably by country of origin: amid the top suppliers, the country with the highest price was Turkey ($X per ton), while the United Arab Emirates amounted to $X per ton.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Turkey (-12.3%).

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports in MENA

In 2022, supplies from abroad of medicaments containing insulin but not antibiotics in measured doses decreased by -4.7% to X tons for the first time since 2019, thus ending a two-year rising trend. Total imports indicated a resilient increase from 2012 to 2022: its volume increased at an average annual rate of +8.5% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. The most prominent rate of growth was recorded in 2013 when imports increased by 32%. Over the period under review, imports hit record highs at X tons in 2021, and then fell in the following year.

In value terms, prophylactic medicaments containing insulin imports stood at $X in 2022. Total imports indicated buoyant growth from 2012 to 2022: its value increased at an average annual rate of +8.0% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, imports decreased by -5.1% against 2020 indices. The most prominent rate of growth was recorded in 2013 with an increase of 25%. Over the period under review, imports attained the maximum at $X in 2020; however, from 2021 to 2022, imports failed to regain momentum.

Imports by Country

Turkey was the key importer of medicaments containing insulin but not antibiotics in measured doses in MENA, with the volume of imports reaching X tons, which was near 37% of total imports in 2022. Algeria (X tons) held the second position in the ranking, followed by Saudi Arabia (X tons) and Iran (X tons). All these countries together took approx. 42% share of total imports. Tunisia (X tons), Israel (X tons), Morocco (X tons), the United Arab Emirates (X tons) and Oman (X tons) followed a long way behind the leaders.

From 2012 to 2022, average annual rates of growth with regard to prophylactic medicaments containing insulin imports into Turkey stood at +5.6%. At the same time, Iran (+28.3%), Tunisia (+23.1%), Israel (+16.7%), Saudi Arabia (+13.7%), Oman (+12.0%), Morocco (+8.5%), the United Arab Emirates (+7.2%) and Algeria (+5.7%) displayed positive paces of growth. Moreover, Iran emerged as the fastest-growing importer imported in MENA, with a CAGR of +28.3% from 2012-2022. While the share of Iran (+9.4 p.p.), Saudi Arabia (+4.7 p.p.), Tunisia (+3 p.p.) and Israel (+2 p.p.) increased significantly in terms of the total imports from 2012-2022, the share of Algeria (-5.2 p.p.) and Turkey (-11.6 p.p.) displayed negative dynamics. The shares of the other countries remained relatively stable throughout the analyzed period.

In value terms, the largest prophylactic medicaments containing insulin importing markets in MENA were Algeria ($X), Saudi Arabia ($X) and Turkey ($X), together accounting for 62% of total imports. Iran, the United Arab Emirates, Israel, Tunisia, Oman and Morocco lagged somewhat behind, together accounting for a further 29%.

Iran, with a CAGR of +24.3%, recorded the highest rates of growth with regard to the value of imports, in terms of the main importing countries over the period under review, while purchases for the other leaders experienced more modest paces of growth.

Import Prices by Country

In 2022, the import price in MENA amounted to $X per ton, rising by 6% against the previous year. Overall, the import price, however, showed a relatively flat trend pattern. The pace of growth appeared the most rapid in 2019 when the import price increased by 24% against the previous year. As a result, import price attained the peak level of $X per ton. From 2020 to 2022, the import prices remained at a somewhat lower figure.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was the United Arab Emirates ($X per ton), while Turkey ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Oman (+4.1%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Platform